drugset
drugset / Trial / NCT00985868

AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors

NCT00985868 ↗

Phase 1 Completed 33 enrolled Cancer Research UK
Open-labelTreatment

Summary

RATIONALE: AT9283 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT9283 in children and adolescents with relapsed and refractory solid tumors.

Timeline

Start
2009-09
Primary completion
2016-01-25
Completion
2019-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject AT9283 Small molecule — Intravenous

Indications

childhood malignant neoplasm